Robert T Babb

8389239, Mar 5, 2013

Jun 4, 2010

12/793898

Gang Chen - Yorktown Heights NY, US
Robert Babb - Nanuet NY, US
James P. Fandl - LaGrangeville NY, US

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

C12P 21/02

435 691, 435353, 435354, 435358, 435366

Expression-enhancing nucleotide sequences for expression in eukaryotic systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Enhanced expression and stability regions (EESYRs) are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells.

20120192300, Jul 26, 2012

Mar 6, 2012

13/412936

Robert Babb - River Edge NJ, US
John McWhirter - Tarrytown NY, US
Lynn MacDonald - White Plains NY, US
Sean Stevens - San Francisco CA, US
Samuel Davis - New York NY, US
David R. Buckler - Chester NJ, US
Andrew J. Murphy - Croton-on-Hudoson NY, US

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

A01K 67/027

800 18

A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making light chain variable regions in mice, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, are provided.

20130045492, Feb 21, 2013

Jun 5, 2012

13/488628

Robert Babb - River Edge NJ, US
John McWhirter - Tarrytown NY, US
Lynn MacDonald - White Plains NY, US
Sean Stevens - San Francisco CA, US
Samuel Davis - New York NY, US
David R. Buckler - Chester NJ, US
Andrew J. Murphy - Croton-on-Hudson NY, US

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

C12P 21/00
G01N 21/64
G01N 33/566

435 792, 436501, 435 696

A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided. Bispecific antibodies capable of binding first and second antigens are provided, wherein the first and second antigens are separate epitopes of a single protein or separate epitopes on two different proteins are provided.

20130130372, May 23, 2013

Jan 29, 2013

13/752647

ROBERT BABB - Nanuet NY, US
JAMES P. FANDL - LaGrangeville NY, US

REGENERON PHARMACEUTICALS, INC. - Tarrytown NY

C12N 15/85

435328, 435326, 435 696

Expression-enhancing nucleotide sequences for expression in eukaryotic systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Enhanced expression and stability regions (EESYRs) are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells.

20220330532, Oct 20, 2022

Jun 4, 2020

17/616295

- Tarrytown NY, US
Johanna Hansen - Greenwich CT, US
Robert Babb - River Edge NJ, US
Chunguang Guo - Briarcliff Manor NY, US
Lynn Macdonald - Harrison NY, US
Andrew J. Murphy - Croton-on-Hudson NY, US

A01K 67/027
C12N 5/0735
C07K 16/06

The present disclosure provides, among other things, genetically modified non-human animals whose germline genome comprises an engineered endogenous immunoglobulin κ light chain locus comprising a single rearranged human immunoglobulin λ light chain variable region operably linked to a non-human Cλ gene segment, where the single rearranged human immunoglobulin λ light chain variable region comprises a human Vλ gene segment and a human Jλ gene segment. All immunoglobulin λ light chains expressed by B cells of the genetically modified non-human animal include human immunoglobulin λ light chain variable domains expressed from the single rearranged human immunoglobulin λ light chain variable region or a somatically hypermutated version thereof. Such animals, tissues from such animals, and cells from such animals represent an effective platform for producing antibodies, e.g., bispecific antibodies.

20220195038, Jun 23, 2022

Dec 22, 2021

17/558645

- Tarrytown NY, US
Ergang Shi - Sleepy Hollow NY, US
Wen-Yi Lee - New Hyde Park NY, US
David Suh - Midland Park NJ, US
Glen Farr - Prospect CT, US
Robert Babb - River Edge NJ, US

C07K 16/28
G01N 33/68

Disclosed are methods for obtaining cells that express antibodies that bind transmembrane proteins, methods for generating antibodies from such cells, antibodies to transmembrane proteins and fragments thereof, and nucleic acids encoding the antibodies. More particularly, the disclosure relates to methods for obtaining antibody-producing cells that express an antibody that binds to a transmembrane protein based on the use of lipid bilayer-membrane scaffold protein complexes to present transmembrane protein antigens to cells.

20210355238, Nov 18, 2021

Mar 17, 2021

17/204253

- Tarrytown NY, US
Andrew J. Murphy - Croton-on-Hudson NY, US
Cagan Gurer - Chappaqua NY, US
Robert Babb - River Edge NJ, US

C07K 16/46
C07K 16/00
C07K 16/28
A01K 67/027

Non-human animals, cells, methods and compositions for making and using the same are provided, wherein the non-human animals and cells comprise an immunoglobulin heavy chain locus that includes unrearranged human immunoglobulin light chain gene segments and an immunoglobulin light chain locus that includes a single rearranged human light chain variable region nucleotide sequence. The unrearranged human light chain gene segments may be operably linked to a heavy chain constant region nucleotide sequence and the rearranged human immunoglobulin light chain variable region nucleotide sequence may be operably linked to a light chain constant region nucleotide sequence. Also provided are methods for obtaining nucleic acid sequences that encode immunoglobulin light chain variable domains capable of binding an antigen in the absence of a cognate variable domain, and expressing such nucleic acid sequences in a host cell, e.g., to generate a multispecific antigen-binding protein.

20210253701, Aug 19, 2021

Mar 19, 2021

17/207462

- Tarrytown NY, US
Lauric Haber - Rye Brook NY, US
Robert Babb - River Edge NJ, US
Gang Chen - Yorktown Heights NY, US
Douglas MacDonald - New York NY, US

C07K 16/28
C07K 16/30
A61P 35/00
C07K 16/40
C07K 16/46

The present invention provides antibodies that bind to CD3 with weak or no detectable binding affinity and methods of using the same. According to certain embodiments, the antibodies of the invention bind human CD3 with low affinity and induce human T cell proliferation and hence induce T cell-mediated killing of tumor cells with high efficacy. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3 with weak or no detectable binding affinity in an in vitro assay, and a second antigen-binding molecule that specifically binds human tumor-associated antigen. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing target antigen, such as PSMA. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial. For example, the antibodies of the invention are useful for the treatment of various cancers or other diseases where immunotherapy, i.e. effector cell immunomodulation is warranted.